Modality
ADC
MOA
IL-13i
Target
BTK
Pathway
Innate Imm
Parkinson'sPsoriasis
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
~Nov 2017
→ ~Feb 2019
NDA/BLA
May 2019
→ Nov 2030
NDA/BLACurrent
NCT03637239
19 pts·Parkinson's
2019-05→2030-11·Not yet recruiting
19 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-042mo awayConference· Psoriasis
2030-11-054.6y awayPh3 Readout· Parkinson's
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Conference
2026-06-04 · 2mo away
Psoriasis
Ph3 Readout
2030-11-05 · 4.6y away
Parkinson's
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03637239 | NDA/BLA | Parkinson's | Not yet recr... | 19 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |